PepsRadar
⌕ Search✧ Ask
Appetite, blood sugar, and energy metabolism.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT). Its featured evidence concerns cultured adipocytes and obese mice, rather than demonstrated weight loss in people.
Related compounds
Read the studies →Adipotide is a peptidomimetic designed to target blood vessels in adipose tissue. Its featured study reported weight-related changes in obese monkeys and also identified kidney effects.
Research topics
Read the studies →AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects. Animal experiments and the later human obesity program tell different parts of its story.
Research topics
Read the studies →Cagrilintide is an amylin analogue investigated for weight management. Its evidence must be separated from evidence for combinations containing it.
Research topics
Read the studies →Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Prescription medicines
Read the studies →Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the studies →Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.
Prescription medicines
Read the studies →Ghrelin is a peptide hormone involved in appetite signaling. A small human crossover experiment found higher food intake after an acute infusion.
Research topics
Read the studies →Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.
Prescription medicines
Read the studies →HGH Fragment 176-191 is a label for a growth-hormone C-terminal fragment. The selected primary paper studied the related 177-191 fragment, so it is background evidence rather than confirmation of the exact 176-191 product.
Research topics
Read the studies →Human insulin replaces or supplements insulin activity in diabetes. Different formulations have different onset and duration, making product identity especially important.
Prescription medicines
Read the studies →L-Carnosine is a dipeptide investigated in metabolic and cellular research. A small oral-supplement pilot examined insulin and glucose-related measures in adults without diabetes.
Research topics
Read the studies →Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Prescription medicines
Read the studies →Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.
Research topics
Read the studies →Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the studies →MK-677, or ibutamoren, is a small-molecule ghrelin mimetic. A trial in older adults found increased fat-free mass without an improvement in strength or physical function.
Related compounds
Read the studies →MOTS-c is a 16-amino-acid peptide studied as a mitochondrial signal. Its metabolic research is frequently discussed alongside exercise and aging.
Research topics
Read the studies →Nesfatin-1 is a NUCB2-derived peptide investigated in feeding regulation. Its foundational evidence involved central administration and signaling experiments in rats.
Research topics
Read the studies →Neuropeptide Y is an endogenous signaling peptide involved in feeding circuitry. The selected mouse study examined NPY-related neurons and feeding behavior rather than a clinical peptide treatment.
Research topics
Read the studies →Nisotirostide is a selective NPY2 receptor agonist investigated as an adjunct to GLP-1 treatment. The selected publication combines laboratory experiments with a small phase 1 human study.
Investigational
Read the studies →Orexin-A, also known as hypocretin-1, is a hypothalamic signaling peptide. The foundational paper identified orexin peptides and receptors and studied feeding responses in rats.
Research topics
Read the studies →Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the studies →Peptide YY is a gut-hormone family involved in feeding regulation. The selected trial studied PYY3-36 alone and with GLP-1; the combined result should not be described as a proven PYY-alone effect.
Research topics
Read the studies →Pramlintide is an adjunctive diabetes medicine used with mealtime insulin in selected patients. It does not replace insulin.
Prescription medicines
Read the studies →Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the studies →Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Prescription medicines
Read the studies →Setmelanotide is a melanocortin-4 receptor agonist studied in rare genetic forms of obesity. The featured trials enrolled people with POMC or LEPR deficiency, rather than general-population obesity.
Prescription medicines
Read the studies →Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the studies →Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Prescription medicines
Read the studies →Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the studies →
